In The Know with Gino: Erlanger Urology Makes Medical Breakthrough with Robotic HIFU Procedure for Prostate Cancer

Online Marketing Higeoqjs Ie UnsplashPhoto by Online Marketing on Unsplash

Chattanooga, TN – In a groundbreaking development for prostate cancer treatment, Erlanger Urology in Chattanooga has become the first medical facility in Tennessee to successfully perform the noninvasive Focal One Robotic High Intensity Focused Ultrasound (HIFU) procedure. Dr. Amar Singh, a highly regarded urologist specializing in Urological Oncology and Robotic Minimally Invasive Surgery, carried out three of these innovative procedures on Tuesday.

Focal One Robotic HIFU represents the pinnacle of precision-focused ablation of diseased prostate tissue. This cutting-edge technology combines real-time ultrasound image guidance with magnetic resonance imaging (MRI) and biopsy data, presenting a comprehensive 3D visualization.

Utilizing a probe, the doctor can navigate directly to the tumor in real-time, directing high-speed ultrasound energy specifically at the target area. This targeted approach allows for the ablation of only the diseased portion of the prostate without the need for any incisions. Robotic HIFU is currently being offered to patients diagnosed with localized prostate cancer.

The integration of these advanced technologies empowers urologists to establish more precise contours around cancerous tumors than ever before. Most importantly, this allows them to ablate a smaller portion of the prostate, significantly reducing damage to surrounding healthy tissue. This groundbreaking technique also minimizes the risk of side effects such as urinary incontinence and erectile dysfunction, which are commonly associated with radical prostatectomy and radiation treatments.

Prostate cancer is one of the most prevalent forms of cancer among men, with early detection being crucial for successful treatment. The advent of the Focal One Robotic HIFU procedure at Erlanger Urology provides patients in Tennessee with a cutting-edge treatment option that combines state-of-the-art imaging and robotic technology to deliver precise and effective care.

The success of the initial procedures performed by Dr. Amar Singh marks a significant milestone in the field of urology, cementing Erlanger Urology’s position as a regional leader in prostate cancer and kidney-sparing surgeries. With this breakthrough, the medical community anticipates a positive impact on patient outcomes and improved quality of life for those diagnosed with localized prostate cancer.

Erlanger Urology plans to continue offering the Focal One Robotic HIFU procedure to eligible patients as part of their comprehensive approach to prostate cancer treatment. The medical community eagerly awaits further developments in this groundbreaking field and anticipates the positive impact this breakthrough will have on patients in Tennessee and beyond.

SOURCE: Chattanoogan